The Pediatric Solid Tumor Program at UF Health treats children and teens with a variety of solid malignancies, from bone and soft-tissue tumors to liver, adrenal, and kidney tumors. Our team will provide your child with a comprehensive treatment plan that is specific to his/her tumor type. In addition to the individual attention your child will receive from your primary oncologist, your child will benefit from the collective expertise of the entire solid tumor treatment group.
Our team includes the following members:
- A dedicated pediatric oncology team who are well-versed in the most recent treatment innovations
- Expert orthopedic oncologists and pediatric surgeons with extensive experience in all types of pediatric cancers
- Radiation oncologists with access to leading-edge technology, including radiation therapy using protons
- Expert pathologists who use molecular diagnostic testing to identify the tumor type
- A Quality of Life Program team who focuses on supportive measures that will help your child and family live the best lives possible, despite the diagnosis of a life-limiting or life-threatening disease.
- Reproductive fertility experts who provide options for fertility preservation before starting treatment
We also draw on the expertise of a variety of support staff, including nurses, clinical pharmacists, social workers, nutritionists, physical therapists, occupational therapists, and child life specialists.
Dr. Joanne Lagmay, Director of the Pediatric Solid Tumor Program, collaborates with members of the Veterinary Medicine, Radiological Engineering, Chemistry, Materials Science, and Radiation Oncology in the development of polymer‐mediated radionuclide therapies in an osteosarcoma canine model. She is also collaborating with Elias Sayour, M.D., Ph.D. in the cellular immunotherapy laboratory at UF in developing an early phase trial for recurrent pediatric solid tumors. The NIH RO1 funded Musculoskeletal Oncology Laboratory headed by orthopedic oncologist Dr. Charles Parker Gibbs focuses on the molecular differences of the cells within individual patients’ tumors, identifying key cellular pathways responsible for tumor initiation in osteosarcoma. His lab is developing novel methods to induce reversal of the malignant character of cells in a patient’s tumor.
Through local and national partnerships, the Pediatric Solid Tumor Program has been successful in enrolling patients in novel clinical trials. Such participation in clinical research efforts allows us to provide patients and families with access to both expert, state-of-the-art care, as well as clinical trial options.